Quest Diagnostics Inc. (DGX) — Analysis Summary
Quest Diagnostics Inc. (DGX) has a market cap of $22.95B with year-over-year revenue growth of +11.8%. Net margin stands at 9.0%. The stock trades at a P/E ratio of 22.4.
Key Takeaways
- Revenue changed +11.8% year-over-year
- Net margin of 9.0%
- P/E ratio of 22.4
Compared to other companies in the SERVICES-MEDICAL LABORATORIES sector, DGX posted revenue growth of +11.8% and trades at a P/E of 22.4.
Quest Diagnostics Inc. (DGX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Sector
SERVICES-MEDICAL LABORATORIES
Employees
57,000
Headquarters
SECAUCUS, NJ
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$3.44
Dividend Yield
1.67%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.